Connect with us

Business

Column: Two key antiabortion studies have been retracted as junk science. Will the Supreme Court care?

Published

on

Column: Two key antiabortion studies have been retracted as junk science. Will the Supreme Court care?

If the effort to ban medication abortion now before the Supreme Court demonstrates anything, it’s that the damage caused in our society by junk science can be disastrous indeed.

That’s the implication of the retraction of two scientific studies, announced Monday by the journal publisher Sage. The studies provided the purported rationale for a Texas federal judge’s ruling overturning the approval of the abortion drugs by the Food and Drug Administration.

It’s impossible to overstate the potential ramifications of the ruling issued April 7 by federal Judge Matthew Kacsmaryk of Amarillo, Texas, which invalidated FDA approvals of the drug mifepristone dating back to 2000.

Experts identified…unjustified or incorrect factual assumptions, material errors in the authors’ analysis of the data, and misleading presentations of the data that…demonstrate a lack of scientific rigor and invalidate the authors’ conclusions in whole or in part.

— Retraction notice of research on mifepristone

Advertisement

Kacsmaryk’s ruling was the basis for an outstandingly loopy decision by the U.S. 5th Circuit Court of Appeals on Aug. 19, which narrowed his ruling somewhat but not entirely. The Supreme Court has scheduled oral arguments on the case for March 26.

The worst-case scenario is that the Supreme Court will follow Kacsmaryk in revoking the FDA’s approval. That would block access to what has become the most common abortion method in the U.S. Providers would have to shift to other medications that are not as effective as mifepristone.

The court could also narrow the reach of the FDA’s actions in 2000, when it declared mifepristone safe and effective, and in 2016 and 2021, when it allowed patients to order the drug online and receive it by mail or from pharmacies rather than at doctors’ offices.

The court could restore previous rules limiting the use of mifepristone to the first seven weeks of gestation instead of the current 10 weeks. It could require that it be administered only through a physician’s prescription and only directly by doctors.

The damage could go further. An expansive Supreme Court ruling could cripple the FDA’s authority to determine the safety and efficacy of drugs and subject its judgments to increasingly partisan challenges. It could bring an antique, long-disregarded 150-year-old antipornography law to legal prominence.

Advertisement

Let’s start at the beginning, with Kacsmaryk’s 2023 ruling. As I’ve reported in the past, Kacsmaryk’s jurisprudence has been a blot on the judicial system since he joined the court in 2019 as a Trump appointee. Kacsmaryk is the only federal judge in the Amarillo district of the federal court in the Northern District of Texas.

That has made his courthouse a favored venue for right-wing litigants. A former functionary of a conservative Christian legal group, he has been a dependable foe of efforts to protect LGBTQ+ legal rights and access to contraceptives.

His record made him the ideal judge for a coalition of antiabortion groups including the American Assn. of Pro-Life Obstetricians & Gynrecologists and the Christian Medical & Dental Associations waging an attack on medication abortion.

Kacsmaryk’s April 7 ruling bristled with antiabortion terminology such as the terms “unborn human” and “unborn child”; abortion providers were labeled “abortionists.” By contrast, a ruling protecting access to mifepristone issued the same day by federal Judge Thomas Owens Rice of Washington state, an Obama appointee, used neutral language, such as a reference to “institutions and providers who provide abortion care.”

Kacsmaryk accepted common talking points of the antiabortion movement as legal conclusions. He cited the Comstock Act, an antipornography law enacted in 1873, no fewer than 29 times. He accepted as read the antiabortion movement’s contention that it barred the shipment of mifepristone through the U.S. mail, even though federal courts had rejected that interpretation for more than 100 years.

Advertisement

He questioned the FDA’s judgment that the drug was safe and effective, despite overwhelming evidence to the contrary. The core of Kacsmaryk’s findings questioning the FDA’s approval of the drug came from two studies led by James Studnicki, director of data analytics at the Charlotte Lozier Institute, which says in the mission statement on its website that it “advises and leads the pro-life movement with groundbreaking scientific, statistical, and medical research.”

Among the institute’s principal aims is “to warn women about the dangers of chemical abortion and expose the harms of the FDA’s current abortion pill policy that simply ignores the known risks.”

Kacsmaryk cited the Studnicki papers to endorse the plaintiff organizations’ conclusions that adverse reactions to mifepristone could “overwhelm the medical system and place ‘enormous pressure and stress’” on doctors due to “significant complications requiring medical attention,” and that women taking the drug were reporting to emergency rooms at much greater rates than those who had undergone surgical abortions.

Sage’s retraction notice explodes those claims. The papers were published in 2021 and 2022 in Sage’s Health Services Research and Managerial Epidemiology journal. (A third Studnicki paper published in 2019 but not cited by Kacsmaryk was also retracted.)

Sage’s inquiry was triggered by Chris Adkins, a pharmaceutical sciences professor at South University School of Pharmacy in Savannah, Ga.

Advertisement

Among the flaws Adkins pointed to was that one study appeared to inflate claims about adverse reactions to the drug by failing to distinguish ER visits for routine complaints from those due to the drug. Nor did the Studnicki research factor in the increases in medication abortions starting in 2000 or the increase in Medicaid enrollments in the same period, which was a factor in the growth of medication abortions.

Sage said that in its pre-retraction review, “experts identified fundamental problems with the design … and methodology” of the questioned papers, as well as “unjustified or incorrect factual assumptions, material errors in the authors’ analysis of the data, and misleading presentations of the data that … demonstrate a lack of scientific rigor and invalidate the authors’ conclusions in whole or in part.”

Sage also noted that the papers declared that the authors had no conflicts of interest in researching and writing the papers. In fact, all but one of the authors of the studies Kacsmaryk cited were affiliated with the Charlotte Lozier Institute, the American Assn. of Pro-Life Obstetricians and Gynecologists, or the Elliot Institute, which are antiabortion advocacy organizations. Although the authors had disclosed their affiliations, Sage reported, they had not acknowledged that these posed a conflict.

Studnicki objects to the retractions, responding that the action is “unjustified” and that his data are “accurately reported.”

Kacsmaryk’s ruling has caused immense confusion in the administration of mifepristone. The 5th Circuit appeals court overturned his rejection of the FDA’s original 2000 conclusion that mifepristone is safe and effective, but upheld his overturning of the FDA’s loosening of restrictions on the use of the drug issued in 2016 and 2021. It stayed injunctions on those uses until the Supreme Court rules, however.

Advertisement

The appeals court opinion featured one of the more curious flights of fancy by a federal judge — a separate opinion by Appellate Justice James C. Ho, another Trump appointee. He advocated overturning the 2000 FDA approval as well as the 2016 and 2021 revisions, on the grounds that abortions cause “aesthetic injury” to doctors forced to participate in the procedure, even if only by treating patients for adverse reactions.

“Unborn babies are a source of profound joy for those who view them,” Ho wrote. “Doctors delight in working with their unborn patients — and experience an aesthetic injury when they are aborted.”

The real injury that could arise from the Supreme Court’s consideration of mifepristone would be to the use of science to validate judicial opinions by substituting junk science for rigorous research.

More than 20 years of medical practice has established that the drug is safe and effective for its purpose — indeed, safer than many other drugs in common use in the U.S. Revoking its approval would be based on no scientific evidence at all, only on politics. And that won’t be good for anyone.

Advertisement

Business

Trump orders federal agencies to stop using Anthropic’s AI after clash with Pentagon

Published

on

Trump orders federal agencies to stop using Anthropic’s AI after clash with Pentagon

President Trump on Friday directed federal agencies to stop using technology from San Francisco artificial intelligence company Anthropic, escalating a high-profile clash between the AI startup and the Pentagon over safety.

In a Friday post on the social media site Truth Social, Trump described the company as “radical left” and “woke.”

“We don’t need it, we don’t want it, and will not do business with them again!” Trump said.

The president’s harsh words mark a major escalation in the ongoing battle between some in the Trump administration and several technology companies over the use of artificial intelligence in defense tech.

Anthropic has been sparring with the Pentagon, which had threatened to end its $200-million contract with the company on Friday if it didn’t loosen restrictions on its AI model so it could be used for more military purposes. Anthropic had been asking for more guarantees that its tech wouldn’t be used for surveillance of Americans or autonomous weapons.

Advertisement

The tussle could hobble Anthropic’s business with the government. The Trump administration said the company was added to a sweeping national security blacklist, ordering federal agencies to immediately discontinue use of its products and barring any government contractors from maintaining ties with it.

Defense Secretary Pete Hegseth, who met with Anthropic’s Chief Executive Dario Amodei this week, criticized the tech company after Trump’s Truth Social post.

“Anthropic delivered a master class in arrogance and betrayal as well as a textbook case of how not to do business with the United States Government or the Pentagon,” he wrote Friday on social media site X.

Anthropic didn’t immediately respond to a request for comment.

Anthropic announced a two-year agreement with the Department of Defense in July to “prototype frontier AI capabilities that advance U.S. national security.”

Advertisement

The company has an AI chatbot called Claude, but it also built a custom AI system for U.S. national security customers.

On Thursday, Amodei signaled the company wouldn’t cave to the Department of Defense’s demands to loosen safety restrictions on its AI models.

The government has emphasized in negotiations that it wants to use Anthropic’s technology only for legal purposes, and the safeguards Anthropic wants are already covered by the law.

Still, Amodei was worried about Washington’s commitment.

“We have never raised objections to particular military operations nor attempted to limit use of our technology in an ad hoc manner,” he said in a blog post. “However, in a narrow set of cases, we believe AI can undermine, rather than defend, democratic values.”

Advertisement

Tech workers have backed Anthropic’s stance.

Unions and worker groups representing 700,000 employees at Amazon, Google and Microsoft said this week in a joint statement that they’re urging their employers to reject these demands as well if they have additional contracts with the Pentagon.

“Our employers are already complicit in providing their technologies to power mass atrocities and war crimes; capitulating to the Pentagon’s intimidation will only further implicate our labor in violence and repression,” the statement said.

Anthropic’s standoff with the U.S. government could benefit its competitors, such as Elon Musk’s xAI or OpenAI.

Sam Altman, chief executive of OpenAI, the company behind ChatGPT and one of Anthropic’s biggest competitors, told CNBC in an interview that he trusts Anthropic.

Advertisement

“I think they really do care about safety, and I’ve been happy that they’ve been supporting our war fighters,” he said. “I’m not sure where this is going to go.”

Anthropic has distinguished itself from its rivals by touting its concern about AI safety.

The company, valued at roughly $380 billion, is legally required to balance making money with advancing the company’s public benefit of “responsible development and maintenance of advanced AI for the long-term benefit of humanity.”

Developers, businesses, government agencies and other organizations use Anthropic’s tools. Its chatbot can generate code, write text and perform other tasks. Anthropic also offers an AI assistant for consumers and makes money from paid subscriptions as well as contracts. Unlike OpenAI, which is testing ads in ChatGPT, Anthropic has pledged not to show ads in its chatbot Claude.

The company has roughly 2,000 employees and has revenue equivalent to about $14 billion a year.

Advertisement
Continue Reading

Business

Video: The Web of Companies Owned by Elon Musk

Published

on

Video: The Web of Companies Owned by Elon Musk

new video loaded: The Web of Companies Owned by Elon Musk

In mapping out Elon Musk’s wealth, our investigation found that Mr. Musk is behind more than 90 companies in Texas. Kirsten Grind, a New York Times Investigations reporter, explains what her team found.

By Kirsten Grind, Melanie Bencosme, James Surdam and Sean Havey

February 27, 2026

Continue Reading

Business

Commentary: How Trump helped foreign markets outperform U.S. stocks during his first year in office

Published

on

Commentary: How Trump helped foreign markets outperform U.S. stocks during his first year in office

Trump has crowed about the gains in the U.S. stock market during his term, but in 2025 investors saw more opportunity in the rest of the world.

If you’re a stock market investor you might be feeling pretty good about how your portfolio of U.S. equities fared in the first year of President Trump’s term.

All the major market indices seemed to be firing on all cylinders, with the Standard & Poor’s 500 index gaining 17.9% through the full year.

But if you’re the type of investor who looks for things to regret, pay no attention to the rest of the world’s stock markets. That’s because overseas markets did better than the U.S. market in 2025 — a lot better. The MSCI World ex-USA index — that is, all the stock markets except the U.S. — gained more than 32% last year, nearly double the percentage gains of U.S. markets.

That’s a major departure from recent trends. Since 2013, the MSCI US index had bested the non-U.S. index every year except 2017 and 2022, sometimes by a wide margin — in 2024, for instance, the U.S. index gained 24.6%, while non-U.S. markets gained only 4.7%.

Advertisement

The Trump trade is dead. Long live the anti-Trump trade.

— Katie Martin, Financial Times

Broken down into individual country markets (also by MSCI indices), in 2025 the U.S. ranked 21st out of 23 developed markets, with only New Zealand and Denmark doing worse. Leading the pack were Austria and Spain, with 86% gains, but superior records were turned in by Finland, Ireland and Hong Kong, with gains of 50% or more; and the Netherlands, Norway, Britain and Japan, with gains of 40% or more.

Investment analysts cite several factors to explain this trend. Judging by traditional metrics such as price/earnings multiples, the U.S. markets have been much more expensive than those in the rest of the world. Indeed, they’re historically expensive. The Standard & Poor’s 500 index traded in 2025 at about 23 times expected corporate earnings; the historical average is 18 times earnings.

Advertisement

Investment managers also have become nervous about the concentration of market gains within the U.S. technology sector, especially in companies associated with artificial intelligence R&D. Fears that AI is an investment bubble that could take down the S&P’s highest fliers have investors looking elsewhere for returns.

But one factor recurs in almost all the market analyses tracking relative performance by U.S. and non-U.S. markets: Donald Trump.

Investors started 2025 with optimism about Trump’s influence on trading opportunities, given his apparent commitment to deregulation and his braggadocio about America’s dominant position in the world and his determination to preserve, even increase it.

That hasn’t been the case for months.

”The Trump trade is dead. Long live the anti-Trump trade,” Katie Martin of the Financial Times wrote this week. “Wherever you look in financial markets, you see signs that global investors are going out of their way to avoid Donald Trump’s America.”

Advertisement

Two Trump policy initiatives are commonly cited by wary investment experts. One, of course, is Trump’s on-and-off tariffs, which have left investors with little ability to assess international trade flows. The Supreme Court’s invalidation of most Trump tariffs and the bellicosity of his response, which included the immediate imposition of new 10% tariffs across the board and the threat to increase them to 15%, have done nothing to settle investors’ nerves.

Then there’s Trump’s driving down the value of the dollar through his agitation for lower interest rates, among other policies. For overseas investors, a weaker dollar makes U.S. assets more expensive relative to the outside world.

It would be one thing if trade flows and the dollar’s value reflected economic conditions that investors could themselves parse in creating a picture of investment opportunities. That’s not the case just now. “The current uncertainty is entirely man-made (largely by one orange-hued man in particular) but could well continue at least until the US mid-term elections in November,” Sam Burns of Mill Street Research wrote on Dec. 29.

Trump hasn’t been shy about trumpeting U.S. stock market gains as emblems of his policy wisdom. “The stock market has set 53 all-time record highs since the election,” he said in his State of the Union address Tuesday. “Think of that, one year, boosting pensions, 401(k)s and retirement accounts for the millions and the millions of Americans.”

Trump asserted: “Since I took office, the typical 401(k) balance is up by at least $30,000. That’s a lot of money. … Because the stock market has done so well, setting all those records, your 401(k)s are way up.”

Advertisement

Trump’s figure doesn’t conform to findings by retirement professionals such as the 401(k) overseers at Bank of America. They reported that the average account balance grew by only about $13,000 in 2025. I asked the White House for the source of Trump’s claim, but haven’t heard back.

Interpreting stock market returns as snapshots of the economy is a mug’s game. Despite that, at her recent appearance before a House committee, Atty. Gen. Pam Bondi tried to deflect questions about her handling of the Jeffrey Epstein records by crowing about it.

“The Dow is over 50,000 right now, she declared. “Americans’ 401(k)s and retirement savings are booming. That’s what we should be talking about.”

I predicted that the administration would use the Dow industrial average’s break above 50,000 to assert that “the overall economy is firing on all cylinders, thanks to his policies.” The Dow reached that mark on Feb. 6. But Feb. 11, the day of Bondi’s testimony, was the last day the index closed above 50,000. On Thursday, it closed at 49,499.50, or about 1.4% below its Feb. 10 peak close of 50,188.14.

To use a metric suggested by economist Justin Wolfers of the University of Michigan, if you invested $48,488 in the Dow on the day Trump took office last year, when the Dow closed at 48,448 points, you would have had $50,000 on Feb. 6. That’s a gain of about 3.2%. But if you had invested the same amount in the global stock market not including the U.S. (based on the MSCI World ex-USA index), on that same day you would have had nearly $60,000. That’s a gain of nearly 24%.

Advertisement

Broader market indices tell essentially the same story. From Jan. 17, 2025, the last day before Trump’s inauguration, through Thursday’s close, the MSCI US stock index gained a cumulative 16.3%. But the world index minus the U.S. gained nearly 42%.

The gulf between U.S. and non-U.S. performance has continued into the current year. The S&P 500 has gained about 0.74% this year through Wednesday, while the MSCI World ex-USA index has gained about 8.9%. That’s “the best start for a calendar year for global stocks relative to the S&P 500 going back to at least 1996,” Morningstar reports.

It wouldn’t be unusual for the discrepancy between the U.S. and global markets to shrink or even reverse itself over the course of this year.

That’s what happened in 2017, when overseas markets as tracked by MSCI beat the U.S. by more than three percentage points, and 2022, when global markets lost money but U.S. markets underperformed the rest of the world by more than five percentage points.

Economic conditions change, and often the stock markets march to their own drummers. The one thing less likely to change is that Trump is set to remain president until Jan. 20, 2029. Make your investment bets accordingly.

Advertisement
Continue Reading

Trending